Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/6/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Andrew Mazar?

Andrew P. Mazar

Founder, Director, Chief Scientific Officer

Monopar

Email: a***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Monopar

Company Description

Monopar's mission is to develop life-altering orphan oncology therapeutics. Welcome to Monopar Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds. Monopar's lead compound, huATN-658, is a novel monoc... more

Find other employees at this company (1)

Background Information

Employment History

Vice President, Biology

Angstrom Pharmaceuticals , Inc.


Consulting Head of Product Development

Lung Therapeutics Inc


Director, Center for Developmental Therapeutics

Northwestern University


Manager

Traverse Independence


Adjunct Professor, Pharmacology

Feinberg School of Medicine at Northwestern University


Development Consultant

Wilson Therapeutics AB


Chief Scientific Officer

Attenuon , LLC


Affiliations

Tactic Pharma LLC

Managing Member and Consulting Chief Scientific Officer


NCI

Charter Member On the Developmental Therapeutics Study Section


National Institutes of Health

Member of Study Sections


Education

Ph.D.

Biochemistry

University of Illinois College of Medicine


Web References(46 Total References)


Monopar

monopartherapeutics.com [cached]

Andrew P. Mazar, PhD
Co-Founder and Chief Scientific Officer Dr. Mazar has spent twenty five years working on drug discovery and development at the interface of academia and industry and has founded or co-founded eight start-up companies to commercialize new drug discoveries. He is also internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis as well as basic mechanisms of cancer metastasis. He is the co-author of 99 peer reviewed publications and 16 reviews and book chapters. Prior to co-founding Tactic Pharmaceuticals in 2010 and joining the Chemistry of Life Processes Institute at Northwestern University in 2009, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC in San Diego from 2000 to 2009 and led discovery and development efforts resulting in three drugs entering oncology clinical trials. Dr. Mazar has now overseen 11 IND enabling efforts, many of these focused on drugs discovered in academia.


www.sec.gov


Andrew P. Mazar 5 Revere Dr, Suite 200 Northbrook IL ILLINOIS 60062 Executive Officer Director


Monopar

www.monopartherapeutics.com [cached]

Andrew P. Mazar, PhD
Co-Founder and Chief Scientific Officer Dr. Mazar has spent twenty five years working on drug discovery and development at the interface of academia and industry and has founded or co-founded eight start-up companies to commercialize new drug discoveries. He is also internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis as well as basic mechanisms of cancer metastasis. He is the co-author of 99 peer reviewed publications and 16 reviews and book chapters. Prior to co-founding Tactic Pharmaceuticals in 2010 and joining the Chemistry of Life Processes Institute at Northwestern University in 2009, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC in San Diego from 2000 to 2009 and led discovery and development efforts resulting in three drugs entering oncology clinical trials. Dr. Mazar has now overseen 11 IND enabling efforts, many of these focused on drugs discovered in academia.


International Protease Network - People

www.protease.net [cached]

Professor Andrew P. Mazar, Ph. D.
Chief Scientific Officer, Senior Vice President, Research and Development Attenuon, L.L.C., 10130 Sorrento Valley Rd Suite B, San Diego, CA 92121


lungtx.com

Andrew Mazar, Ph.D.
Andrew Mazar Founder and Head of Product Development Dr. Mazar serves as Head of Product Development in addition to his current position as Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence at Northwestern University. Prior to this, Dr. Mazar was most recently the Chief Scientific Officer at Attenuon, LLC and has led three projects at Attenuon through IND and into phase II trials. He is currently managing an additional three projects at various stages of IND enabling development. Prior to Attenuon, Dr. Mazar had significant input in three projects that led two successful INDs, two of which made it through phase II trials and one of which is currently in phase II trials. One of these projects was the original development of scuPA for the treatment of myocardial infarction. Thus, Dr. Mazar has extensive expertise in translating early stage science into clinical projects through phase II clinical development and managing this entire process. He also has direct experience in the development of LTI-01 (scuPA) as a clinical therapeutic agent. During his tenure in biotechnology, Dr. Mazar has led several projects that culminated in several out-license deals as well as funded collaborations. A new partnership deal with a large European venture group on all of Attenuon's projects has closed. During the partnership process, Dr. Mazar led early and late stage discussion with most every large and mid-size biotechnology company interested in cancer therapeutics. During these discussions, terms sheets were obtained from five different suitors, all of them public companies. While at Attenuon, Dr. Mazar managed $63M of investment capital, the majority of this raised through a single investor, during his nine year tenure and led a road show managed by Bank of America.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory